Your browser doesn't support javascript.
loading
Weight of evidence evaluation of the metabolism disrupting effects of triphenyl phosphate using an expert knowledge elicitation approach.
Beausoleil, Claire; Thébault, Anne; Andersson, Patrik; Cabaton, Nicolas J; Ermler, Sibylle; Fromenty, Bernard; Garoche, Clémentine; Griffin, Julian L; Hoffmann, Sebastian; Kamstra, Jorke H; Kubickova, Barbara; Lenters, Virissa; Kos, Vesna Munic; Poupin, Nathalie; Remy, Sylvie; Sapounidou, Maria; Zalko, Daniel; Legler, Juliette; Jacobs, Miriam N; Rousselle, Christophe.
Affiliation
  • Beausoleil C; French Agency for Food, Environmental and Occupational Health and Safety (Anses), 94701 Maisons-Alfort, France. Electronic address: claire.beausoleil@anses.fr.
  • Thébault A; French Agency for Food, Environmental and Occupational Health and Safety (Anses), 94701 Maisons-Alfort, France.
  • Andersson P; Chemistry Department, Umeå University, SE-901 87 Umeå, Sweden.
  • Cabaton NJ; INRAE. UMR1331 Toxalim (Research Center in Food Toxicology), Université de Toulouse, INRAE, ENVT, INP-Purpan, UT3, 31027 Toulouse, France.
  • Ermler S; Department of Life Sciences, Centre of Genome Engineering and Maintenance, College of Health, Medicine and Life Sciences, Brunel University London, UB8 3PH Uxbridge, United Kingdom.
  • Fromenty B; INSERM, Univ Rennes, INRAE, Institut NUMECAN (Nutrition Metabolisms and Cancer) UMR_A 1341, UMR_S 1317, F-35000 Rennes, France.
  • Garoche C; Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université Montpellier, Institut Régional du Cancer de Montpellier (ICM), Montpellier, France.
  • Griffin JL; The Rowett Institute, Foresterhill Health Campus, University of Aberdeen, Aberdeen, UK.
  • Hoffmann S; Seh Consulting + Services, Stembergring 15, 33106 Paderborn, Germany.
  • Kamstra JH; Institute for Risk Assessment Sciences, Department of Population Health Sciences, Utrecht University, Utrecht, the Netherlands.
  • Kubickova B; Radiation, Chemical and Environmental Hazards (RCE), Department of Toxicology, UK Health Security Agency (UKHSA), Harwell Science and Innovation Campus, Chilton OX11 0RQ, Oxon, United Kingdom.
  • Lenters V; Institute for Risk Assessment Sciences, Department of Population Health Sciences, Utrecht University, Utrecht, the Netherlands.
  • Kos VM; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
  • Poupin N; INRAE. UMR1331 Toxalim (Research Center in Food Toxicology), Université de Toulouse, INRAE, ENVT, INP-Purpan, UT3, 31027 Toulouse, France.
  • Remy S; Flemish Institute for Technological Research (VITO), 2400 Mol, Belgium.
  • Sapounidou M; Chemistry Department, Umeå University, SE-901 87 Umeå, Sweden.
  • Zalko D; INRAE. UMR1331 Toxalim (Research Center in Food Toxicology), Université de Toulouse, INRAE, ENVT, INP-Purpan, UT3, 31027 Toulouse, France.
  • Legler J; Institute for Risk Assessment Sciences, Department of Population Health Sciences, Utrecht University, Utrecht, the Netherlands.
  • Jacobs MN; Radiation, Chemical and Environmental Hazards (RCE), Department of Toxicology, UK Health Security Agency (UKHSA), Harwell Science and Innovation Campus, Chilton OX11 0RQ, Oxon, United Kingdom.
  • Rousselle C; French Agency for Food, Environmental and Occupational Health and Safety (Anses), 94701 Maisons-Alfort, France.
Toxicol Appl Pharmacol ; 489: 116995, 2024 Aug.
Article in En | MEDLINE | ID: mdl-38862081
ABSTRACT
Identification of Endocrine-Disrupting Chemicals (EDCs) in a regulatory context requires a high level of evidence. However, lines of evidence (e.g. human, in vivo, in vitro or in silico) are heterogeneous and incomplete for quantifying evidence of the adverse effects and mechanisms involved. To date, for the regulatory appraisal of metabolism-disrupting chemicals (MDCs), no harmonised guidance to assess the weight of evidence has been developed at the EU or international level. To explore how to develop this, we applied a formal Expert Knowledge Elicitation (EKE) approach within the European GOLIATH project. EKE captures expert judgment in a quantitative manner and provides an estimate of uncertainty of the final opinion. As a proof of principle, we selected one suspected MDC -triphenyl phosphate (TPP) - based on its related adverse endpoints (obesity/adipogenicity) relevant to metabolic disruption and a putative Molecular Initiating Event (MIE) activation of peroxisome proliferator activated receptor gamma (PPARγ). We conducted a systematic literature review and assessed the quality of the lines of evidence with two independent groups of experts within GOLIATH, with the objective of categorising the metabolic disruption properties of TPP, by applying an EKE approach. Having followed the entire process separately, both groups arrived at the same conclusion, designating TPP as a "suspected MDC" with an overall quantitative agreement exceeding 85%, indicating robust reproducibility. The EKE method provides to be an important way to bring together scientists with diverse expertise and is recommended for future work in this area.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Organophosphates / Endocrine Disruptors Limits: Animals / Humans Language: En Journal: Toxicol Appl Pharmacol Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Organophosphates / Endocrine Disruptors Limits: Animals / Humans Language: En Journal: Toxicol Appl Pharmacol Year: 2024 Document type: Article